Present State of Propofol Shortage

A few months ago, the ASA in collaboration with the U.S. Food and Drug Administration (FDA) and American Society of Health-System Pharmacists (ASHP) worked together to address the last information on Propofol shortage.

The overlapping recall of Propofol by its manufactures, Hospira and Teva, was due to the contamination in production thereby leading to shortage of it in the U.S. 

Hospira will be able to manufacture it soon, unlike Teva who currently out of production for Propofol and. APP, another manufacturer for propofol vials is currently producing Diprivan to restore the demands. APP is also providing unapproved Propoven, - a single dose vial as an alternative for Propofol to control current requirements. Currently, only APP is authorized to import and distribute Propoven at this time.

Latest update by FDA and ASHP has indicated that the shortage of Propofol will continue for some time and that facilities should remain confident that the practice of the safe use of drugs will continue without affecting its patients.

To learn more about this shortage and other guidelines, see here.

More information on this issue can be found here:

http://www.ashp.org/Import/PRACTICEANDPOLICY/PracticeResourceCenters/DrugShortages/GettingStarted/CurrentShortages/Bulletin.aspx?id=573 
http://www.asahq.org/news/asanews110909.htm

http://www.outpatientsurgery.net/news/2010/03/8

http://www.beckersasc.com/anesthesia/anesthesia/fda-provides-new-updates-to-propofol-shortage-including-authorized-generics.html

Get updates! Follow us on Twitter

Join us. Friend us on Facebook!

^ back to top